BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on Oct. 1, 2025, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase...
Immunome, Inc (NASDAQ: IMNM) has a “rich pipeline of potential best and/or first-in-class targeted oncology therapeutics,” Goldman Sachs analysts wrote in a note to clients on Monday. They initiated coverage on Immunome stock with a ‘Buy' rating and 12-month target price of $26 per share.
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on Sept. 2, 2025, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchas...
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome management will present at the H.C. Wainwright 27th Annual Global Investment Conference on Tuesday, Sept. 9, 2025 at 1:00 p.m. Eastern Time. Interested parties can access the live audio webcast for...
Immunome's lead asset, varegacestat, shows promising efficacy in desmoid tumors, with phase 3 topline data expected by the end of 2025. IMNM holds Orphan Drug designations in the US and Europe, potentially enabling accelerated approval if phase 3 results are positive. Cash reserves of $143.9M and marketable securities of $124.2M provide runway into 2027, despite a high annualized cash burn.
Immunome (IMNM -3.59%), a clinical-stage biotechnology company developing targeted therapies for cancer, reported its second quarter 2025 earnings on August 6, 2025. The standout news was a substantial revenue beat, with $4.0 million in GAAP revenue topping analyst forecasts by a wide margin, plus a narrower-than-expected GAAP loss per share.
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the quarter ended June 30, 2025 and provided a business update. “Immunome made substantial progress in the second quarter of 2025, underscored by the continued advancement of our clinical p...
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.